

Amwill Health Care Limited (Formerly known as Amwill Health Care Private Limited)

CIN: U36994KA2017PLC105721

Special Purpose Interim Balance Sheet as at 31 December 2023

(All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

Particulars	Note	As at 31 December 2023	As at 31 March 2023
EQUITY AND LIABILITIES			
Shareholder's funds			
Share capital	3	5.00	3.00
Reserves and surplus	4	1,557.63	460.87
Sub-total (A)		1,562.63	463.87
Non-current liabilities			
Long-term provisions	5	29.38	26.85
Sub-total (B)		29.38	26.85
Current liabilities			
Short term borrowings	6	-	3.50
Trade payables	7		
- due to micro and small enterprises		107.74	303.51
- due to other than micro and small enterprises		11.46	214.89
Other current liabilities	8	174.51	230.41
Short-term provisions	9	128.64	0.06
Sub-total (C)		422.35	752.37
Total (A+B+C)		2,014.36	1,243.09
ASSETS			
Non-current assets			
Property, plant and equipment			
- Tangible assets	10	60.95	48.95
- Intangible assets	11	2.59	3.10
- Capital Work in Progress	12	21.25	-
- Intangible assets under development	13	17.65	-
Deferred tax asset (net)	14	8.91	14.07
Long term loans and advances	15	4.99	4.99
Other non-current assets	16	-	33.58
Sub-total (A)		116.34	104.69
Current assets			
Inventories	17	104.63	317.96
Trade receivables	18	803.23	123.20
Cash and cash equivalents	19	745.70	584.04
Other bank balances	19	102.85	101.32
Short-term loans and advances	20	126.52	5.53
Other current assets	21	15.09	6.35
Sub-total (B)		1,898.02	1,138.40
Total (A+B)		2,014.36	1,243.09
Significant accounting policies	1 & 2		
Notes to financial statements	3 to 42		

The notes referred to above form an integral part of the financial statements.

As per our report of even date

For SKLR & Co. LLP
Chartered Accountants
Firm Registration No.: W100362

Latesh Gada
Latesh Gada
Partner

Membership No.: 155999
UDIN No.: 24155999BKAIZO9276

Place: Mumbai
Date: 25-01-2024



For and on behalf of the Board of Directors of
Amwill Health Care Limited (Formerly known as Amwill Health Care
Private Limited)

Tarun Gandhi
Tarun Gandhi
Director
DIN: 07854699

Place: Bangalore
Date: 25-01-2024

Anand Gandhi
Anand Gandhi
Director
DIN: 07854706

Place: Bangalore
Date: 25-01-2024



Jan

Amwill Health Care Limited (Formerly known as Amwill Health Care Private Limited)

CIN: U36994KA2017PLC105721

Special Purpose Interim Statement of Profit and Loss for the period from 1st April 2023 to 31 December 2023


(All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

Particulars	Note	For the period ended 31 December 2023	Year ended 31 March 2023
Income			
Revenue from operations	22	3,578.83	3,016.63
Other Income	23	26.36	11.62
Total Income		3,605.19	3,028.25
Expenses			
Materials produced	24	754.30	1,019.04
Changes in inventories	25	213.33	(112.20)
Employee benefit expenses	26	420.29	762.34
Finance cost	27	4.38	-
Depreciation and amortization expense	28	16.06	23.74
Other expenses	29	719.67	932.41
Total expenses		2,128.03	2,625.33
Profit before tax for the period/ year		1,477.16	402.92
Tax expense			
Current tax	9	375.24	110.20
Deferred tax - charge/ (credit)	14	5.16	(9.23)
Profit after tax for the period/ year		1,096.76	301.95
Basic and diluted earnings per share			
Equity shares [Face value of Rs. 10 each]	32	2,196.14	647.01
Significant accounting policies	1 & 2		
Notes to financial statements	3 to 42		

The notes referred to herein above form an integral part of financial statements.

As per our report of even date

For SKLR & Co. LLP
Chartered Accountants
Firm Registration No.: W100362



Latesh Gada
Partner
Membership No.: 155999
UDIN No.: 24155999BKA1209226

Place: Mumbai
Date: 25/01/2024




For and on behalf of the Board of Directors of
Amwill Health Care Limited (Formerly known as Amwill Health Care
Private Limited)



Tarun Gandhi
Director
DIN: 07854699

Place: Bangalore
Date: 25/01/2024



Anand Gandhi
Director
DIN: 07854706

Place: Bangalore
Date: 25/01/2024



Amwill Health Care Limited (Formerly known as Amwill Health Care Private Limited)
CIN: U36994KA2017PLC105721
Special Purpose Interim Cash Flow Statement for the period from 1st April 2023 to 31 December 2023
(All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

Particulars	Note	For the period ended 31 December 2023	Year ended 31 March 2023
A. CASH FLOW FROM OPERATING ACTIVITIES			
Profit before tax		1,477.16	402.92
Adjustments for :			
Depreciation and amortisation expense		16.06	23.74
Profit on sale of property, plant and equipment		(2.78)	-
Interest income on bank deposits		(23.24)	(9.98)
Interest income on income tax refund		(0.34)	(1.64)
Operating profit/ (loss) before changes in assets and liabilities		1,466.85	415.04
Movements in working capital : [Including Current and Non-current]			
(Increase)/decrease in Trade receivables		(680.03)	(35.68)
(Increase)/decrease in Inventories		213.33	(112.20)
(Increase)/decrease in Loans and advances		(121.00)	19.59
(Increase)/decrease in Other assets		(12.36)	(0.16)
Increase/(decrease) in Trade payables		(399.19)	275.20
Increase/(decrease) in Other liabilities		(55.84)	(9.78)
Increase/(decrease) in Provisions		4.78	26.92
		416.54	578.93
Adjustments for :			
Direct taxes paid [Including tax deducted at source] - (net)		(215.01)	(99.76)
Net cash provided by operating activities (A)		201.53	479.17
B. CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment and capital expenditure made		(69.15)	(31.47)
Proceeds from sale of property, plant and equipment		5.47	-
Interest received		26.85	5.44
Proceeds from maturity of fixed deposits/ (investment) during the year (Net)		(1.53)	(101.32)
Net cash used in investing activities (B)		(38.36)	(127.35)
C. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from issue of share capital		2.00	-
Proceeds from short term borrowings		-	2.52
Repayment of short term borrowings		(3.50)	(11.12)
Net cash used in financing activities (C)		(1.50)	(8.60)
Net Increase / (decrease) in cash and cash equivalents (A+B+C)		161.66	343.24
Cash and cash equivalents at beginning of the period/ year	19	584.04	240.80
Cash and cash equivalents at end of the period/year		745.70	584.04
Net Increase / (decrease) in cash and cash equivalents		161.66	343.24



Amwill Health Care Limited (Formerly known as Amwill Health Care Private Limited)
CIN: U36994KA2017PLC105721
Special Purpose Interim Cash Flow Statement for the period from 1st April 2023 to 31 December 2023
 (All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

Notes :

- 1 Cash flow statement has been prepared as per "indirect method" as set out in AS 3 - "Cash Flow Statement"
- 2 Breakup of cash and cash equivalent is as given below:

Particulars	Note	As at 31 December 2023	As at 31 March 2023
Cash and Cash Equivalents			
- Cash in Hand		8.92	8.65
- Balance with bank in current accounts		444.93	2.09
Fixed deposits with bank- Sweep-in facility		291.85	573.30
Total Cash and Cash Equivalents	19	745.70	584.04

Significant accounting policies	1 & 2
Notes to financial statements	3 to 42

The notes referred to above form an integral part of the financial statements.

As per our report of even date

For SKLR & Co. LLP
 Chartered Accountants
 Firm Registration No.: W100362

Latah Gada

Latah Gada
 Partner
 Membership No. 155999
 UDIN No.: 24155999BKAIZO9276

Place: Mumbai
 Date: 25-01-2024



For and on behalf of the Board of Directors of
Amwill Health Care Limited (Formerly known as Amwill Health Care
Private Limited)

Anand Gandhi

Anand Gandhi
 Director
 DIN: 07854699

Place: Bangalore
 Date: 25-01-2024

Anand Gandhi

Anand Gandhi
 Director
 DIN: 07854706

Place: Bangalore
 Date: 25-01-2024



Amwill Health Care Private Limited

CIN: U36994KA2017PTC105721

Notes to the Special Purpose Financial Statements for the year ended 31 March 2023

1. Corporate Information

Amwill Health Care Private Limited (CIN: U36994KA2017PTC105721) herein referred to as "the Company" was incorporated on 21 August 2017. The registered office of the Company is situated at No. 157, 1st Floor, 2nd MAIN Road, 3rd Cross, Chamrajpet, Bangalore, Karnataka, India, 560018. The Company is engaged in the business of dealing in pharma products.

The Special Purpose Financial Statements were authorised for issue by the Board of Directors on 25 January 2024

2. Significant accounting policies

2.1 Basis of preparation of Special Purpose Financial Statements

The Financial Statement of the Company for the year ended 31 March 2023 were adopted by the Company on 04 September 2023 and audited by another auditor who issued their auditor report dated of the same date. As the predecessor auditor did not hold a peer review certificate at the date of signing of annual report, in order to comply with requirement of Securities and Exchange Board of India (Issue of Share Capital and Disclosure Requirements) Regulation, 2018 ("SEBI ICDR Regulation"), these accounts are getting re-audited by the incoming Peer Review Compliant Auditor in accordance with the applicable standards. Accordingly, these are Special Purpose Financial Statement prepared in order the comply with SEBI ICDR Regulation.

The Special Purpose Financial Statements are prepared in accordance with Indian Generally Accepted Accounting Principles ("GAAP") under the historical cost convention on the accrual basis. GAAP comprises of accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014 as amended from time to time and the Companies Act, 2013.

These Statements have been prepared specifically for inclusion in the Draft Red Herring Prospectus ("DRHP") to be filed by the Company with the SME platform of BSE limited ("BSE SME") in connection with equity fund raised through fresh issue and offer for sale of its equity shares, in accordance with the requirements of:

- a. Section 26 of Part I of Chapter III of the Companies Act, 2013;
- b. Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the "SEBI ICDR Regulations") as issued by the Securities and Exchange Board of India ("SEBI") on 11th September 2018 as amended from time to time; and
- c. Guidance Note on Reports in Company Prospectus (Revised 2019) as issued by the Institute of Chartered Accountants of India ("ICAI")


Accounting policies have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use.

2.2 Presentation and disclosure of Special Purpose Financial Statements

All assets and liabilities have been classified as current & non-current as per Company's normal operating cycle and other criteria set out the Schedule III of the Companies Act, 2013.

As of the reporting date, the Company's operating cycle is considered to be 12 months.

These Special Purpose Financial Statements are presented in Indian Rupees which is the functional currency of the Company. All amounts disclosed in the Special Purpose Financial Statements which also include the accompanying notes have been rounded off to the nearest lakhs up to two decimal places as per the requirement of Schedule III to the Companies Act, 2013, other



than shares and per share amounts, unless otherwise stated. Wherever an amount is represented as INR '0.00' (zero) it construes a value less than rupees five hundred.

2.3 Use of estimates

The preparation of the Special Purpose Interim Financial Statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the application of accounting policies, reported balances of assets and liabilities, disclosure of contingent liabilities as on the date of Special Purpose Interim Financial Statements and reported amounts of income and expenses during the period. Management believes that the estimates and assumptions used in the preparation of Special Purpose Interim Financial Statements are prudent and reasonable. Actual results could differ from those estimates. Any difference between the actual results and estimates are recognised in the period in which the results are known / materialise. Any revision to accounting estimates is recognized prospectively in the current and future periods.

2.4 Investments

Investments are classified into current and long - term investments.

Investments that are readily realizable and intended to be held for not more than a year from the date on which such investments are made are classified as current investments. All other investments are classified as non-current investments.

Current investments are carried at lower of cost and fair value determined on an individual investment basis. Non-current investments are carried at cost. However, provision for diminution in value of long-term investments is made to recognise a decline, other than temporary, on an individual investment basis.

Long term investments which are expected to be realized within twelve months from the balance sheet date are presented under 'current investments' as 'current portion of loan term investments' in accordance with the current / noncurrent classification of investments as per Schedule III of the Companies Act, 2013.

The cost of investments comprises purchase price and directly attributable acquisition charges such as brokerage, fees and duties.


Investment transactions are accounted for on a trade date basis. In determining the holding cost of investments and the gain or loss on sale of investments, the 'weighted average cost' method is followed.

On disposal of an investment, the difference between its carrying amount and net disposal proceeds is charged or credited to the Statement of Profit and Loss.

2.5 Revenue Recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured.

Interest income is recognised on time proportion basis taking into account the amount outstanding and rate applicable.



Dividend income on investment is accounted for in the period/year in which the right to receive the payment is established.

2.6 Borrowing cost

Borrowing costs that are directly attributable to the acquisition, construction or development of a qualifying asset are capitalized as part of the cost of the respective asset till such time the asset is ready for its intended use or sale. A qualifying asset is an asset which necessarily takes substantial period of time to get ready for its intended use or sale. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest, exchange difference arising from foreign currency borrowings to the extent they are treated as an adjustment to the borrowing cost and other costs that an entity incurs in connection with the borrowing of funds.

2.7 Taxes on income

Tax expenses comprises of current tax, deferred tax charge or credit and adjustments of taxes for earlier years

Provision for current tax is made as per the provisions of Income Tax Act, 1961.

Deferred tax charge or credit reflects the impact of current period timing differences between taxable income and accounting income for the period and reversal of timing differences of earlier years and are measured based on the tax rates and the tax laws enacted or substantively enacted at the balance sheet date.

Deferred tax assets are recognised only to the extent there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realised. In situations where the Company has unabsorbed depreciation or carry forward tax losses, all deferred tax assets are recognised only if there is virtual certainty supported by convincing evidence that they can be realised against future taxable profits. Deferred tax assets are reviewed for the appropriateness of their respective carrying amounts at each balance sheet date.

2.8 Cash and cash equivalents

Cash and cash equivalents include cash in hand, bank balances, deposits with bank (other than on lien) and all short term and highly liquid investments that are readily convertible into known amounts of cash and are subject to an insignificant risk of change in value.

2.9 Cash flow statement

Cash flows are reported using the indirect method, whereby net profit/loss before tax is adjusted for the effects of transactions of non-cash nature, any deferrals of accruals of past or future operating cash receipts or payments and item of income or expense associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated.



2.10 Inventories

Inventories are valued at lower of cost or net realisable value. Cost is determined on a First In-First Out (FIFO) basis and includes all applicable costs, including inward freight, incurred in bringing goods to their present location and condition.

Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and estimated costs necessary to make the sale. Provisions are made towards slow-moving and obsolete items based on historical experience of utilisation on a product category basis, which consideration of product lines and market conditions.

2.11 Foreign currency transactions

Transactions in foreign currency are recorded at exchange rates prevailing at the date of transactions. Exchange differences arising on foreign exchange transactions settled during the period/year are recognised in the statement of profit and loss of the period/year.

Monetary assets and liabilities denominated in foreign currencies which are outstanding, as at the reporting period are translated at the closing exchange rates and the resultant exchange differences are recognised in the statement of profit and loss.

Non-monetary assets and liabilities denominated in foreign currencies that are measured in terms of historical cost are translated using the exchange rate at the date of the transaction.

Non-monetary items, which are measured at fair value or other similar valuation denominated in a foreign currency, are translated using the exchange rate at the date when such value was determined.

2.12 Employee benefits

- **Short-term employee benefits**

Employee benefits payable wholly within twelve months of rendering the service are classified as short-term employee benefits. The undiscounted amount of short-term employee benefits expected to be paid in exchange for the services rendered by employees is recognized during the period/year.


- **Post-employment benefits**

- (a) **Defined contribution plans**

Contributions to the provident fund, which is defined contribution scheme, are recognised as an employee benefit expense in the statement of profit and loss in the period in which the contribution is due. Contributions are made in accordance with the rules of the statute and are recognised as expenses when employees render service entitling them to the contributions.

- (b) **Defined benefit plans**

The employees' gratuity scheme is a defined benefit plan. The present value of the obligation under such defined benefit plans is determined based on actuarial valuation using the projected unit credit



method, which recognises each period of service as giving rise to additional unit of employee benefit entitlement and measures each unit separately to build up the final obligation.

The obligation is measured at the present value of the estimated future cash flows. The discount rates used for determining the present value of the obligation under defined benefit plans, is based on the market yields on government securities as at the reporting date, having maturity periods approximating to the terms of related obligations.

In case of funded plans, the fair value of the planned assets is reduced from the gross obligation under the defined benefit plans, to recognise the obligation on net basis.

When the benefits of the plan are changed or when a plan is curtailed, the resulting change in benefits that relates to past service or the gain or loss on curtailment is recognised immediately in the statement of profit and loss. Net interest is calculated by applying the discount rate to the net defined benefit liability or asset. The Company recognises gains/ losses on settlement of a defined plan when the settlement occurs.

2.13 Property, plant and equipment

• Recognition and measurement

Property, plant and equipment are stated at cost, net of accumulated depreciation (other than freehold land) and impairment losses, if any. The cost comprises purchase price, borrowing costs if capitalisation criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use. Capitalisation of costs in the carrying amount of property, plant and equipment ceases when the item is in the location and condition necessary for it to be capable of operating in the manner intended by the Company. Any trade discounts and rebates are deducted in arriving at the purchase price.

The Company identifies and determines cost of each component/ part of the asset separately, if the component/ part has a cost which is significant to the total cost of the asset and has useful life that is materially different from that of the remaining asset. These components are depreciated separately over their useful lives; the remaining components are depreciated over the life of the principal asset.


• Subsequent costs

Subsequent expenditure related to an item of property, plant and equipment is added to its book value only if it increases the future benefits from the existing asset beyond its previously assessed standard of performance. Incomes and expenses related to the incidental operations not necessary to bring the item to the location and the condition necessary for it to be capable of operating in the manner intended by the Company are recognised in the Statement of profit and loss. All other expenses on existing property, plant and equipment, including day-to-day repair and maintenance expenditure and cost of replacing parts, are charged to the Statement of Profit & Loss for the period/year in which such expenses are incurred.

Capital work-in-progress comprises of property, plant and equipment that are not ready for their intended use at the end of reporting period and are carried at cost comprising direct costs, related incidental expenses, other directly attributable costs and borrowing costs.

• Disposal

An item of property, plant and equipment is derecognised upon disposal or when no future benefits are expected from its use or disposal. Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment, and are recognised net within other income/ expenses in the statement of profit and loss.



Jan



- **Depreciation**

Depreciation on Property, plant and equipment's is calculated on pro rata basis on straight-line method using the management assessed useful lives of the assets which is in line with the manner prescribed in Schedule II of the Companies Act, 2013. The useful life is as follows:

Class of asset	Useful lives as per schedule II (Years)	Useful lives considered as per management estimate (Years)
Plant and equipments	15	5
Furniture and fixtures	10	10
Office equipments	5	5
Computers	3	3
Vehicles	8 to 10	8 to 10
Electrical Installations and Equipments	5	5

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at regular intervals and adjusted prospectively, if appropriate.

Leasehold improvements are depreciated over the primary lease period.

2.14 Intangible Assets

- **Recognition and measurement**

Intangible assets are recognised when the asset is identifiable, is within the control of the Company, it is probable that the future economic benefits that are attributable to the asset will flow to the Company and cost of the asset can be reliably measured.

Intangible assets acquired separately are measured on initial recognition at cost. Intangible assets acquired by the Company that have finite useful lives are measured at cost less accumulated amortisation and any accumulated impairment losses. Intangible assets with indefinite useful lives are not amortised, but are tested for impairment annually, either individually or at the cash-generating unit level.

Expenditure on research activities is recognised in the statement of profit and loss as incurred. Development expenditure is capitalised only if the expenditure can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable and the Company intends to complete development and to use or sell the asset.

- **Subsequent measurement**

Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates.

- **Amortisation**

Amortisation is calculated over the cost of the asset, or other amount substituted for cost. Amortisation is recognised in statement of profit and loss on a straight-line basis over the estimated useful lives of intangible assets from the date that they are available for use.

Class of asset	Useful lives considered (In years)
Trademark	5
Computer Software	5



JKR

- Disposal

Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit and loss when the asset is derecognized.

2.15 Provisions, contingent liabilities and contingent assets

A provision is recognised when the Company has a present obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. Provisions are not discounted to its present value (except dismantling / decommissioning liabilities that are recognised as cost of Property, Plant and Equipment) and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not require an outflow of resources. When there is a possible obligation or a present obligation in respect of which likelihood of outflow of resources is remote, no provision or disclosure is made.

Contingent assets are neither disclosed nor recognised.

2.16 Earnings per share

Basic earnings per share are calculated by dividing the net profit or loss (after tax) for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. The weighted average number of equity shares outstanding during the period is adjusted for event of rights issue.

Diluted earnings per share is calculated by dividing the net profit or loss (after tax) for the period attributable to equity shareholders and the weighted average number of equity shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

2.17 Share issue expenses

Share issue expenses are adjusted against securities premium (to the extent available) and statement of profit and loss. Pending issue of shares, same are shown under pre-paid expenses.



3 Share capital	As at	As at
	31 December 2023	31 March 2023
Authorised capital		
2,50,000 (31 March 2023: 2,50,000) equity shares of INR 10 each	25.00	25.00
	25.00	25.00
Issued, subscribed and fully paid-up		
50,000 (31 March 2023: 30,000) equity shares of INR 10 each	5.00	3.00
Total	5.00	3.00

3.1 Terms/ rights attached to equity shares

The Company has a single class of equity shares. All equity shares rank equally with regards to dividends and share in the Company's residual assets. The equity shareholders are entitled to receive dividend as declared from time to time. The voting rights of equity shareholders on a poll are in proportion to its share of the paid-up equity capital of the Company. Voting rights cannot be exercised in respect of shares on which any call or other sums presently payable has not been paid. Failure to pay any amount called up on shares may lead to forfeiture of the shares.

On winding up of the Company, the holders of the equity shares will be entitled to receive the residual assets of the Company, remaining after distribution of all preferential amounts in proportion of the number of equity shares held.

3.2 The reconciliation of the number of shares outstanding and the amount of share capital during the period 31 December 2023 and 31 March 2023 is set out below:

Particulars	31 December 2023		31 March 2023	
	Number of Shares	Amount	Number of Shares	Amount
Number of shares at the beginning	30,000	3.00	30,000	3.00
Add: Shares issued during the period/year (Refer note 3.5)	20,000	2.00	-	-
Less: Buyback during the period/year	-	-	-	-
Number of shares at the end	50,000	5.00	30,000	3.00

3.3 Equity shares held by each shareholder holding more than 5% shares

Particulars	As at 31 December 2023		As at 31 March 2023	
	% of holding	Number of Shares	% of holding	Number of Shares
Tarun Gandhi	40.57%	20,285	33.33%	10,000
Anand Gandhi	40.57%	20,285	33.33%	10,000
Shashikala	4.95%	2,475	33.33%	10,000
	86.09%	43,045	100.00%	30,000

3.4 Disclosures of Shareholdings of Promoter and Promoter group is set out below:

Sr No.	Name of the Promoter/ Promoter group	As at 31 December 2023		As at 31 March 2023		% change during the period/year
		No. of Shares	% of total shares	No. of Shares	% of total shares	
1	Tarun Gandhi	20,285	40.57%	10,000	33.33%	7.24%
2	Anand Gandhi	20,285	40.57%	10,000	33.33%	7.24%
3	Shashikala	2,475	4.95%	10,000	33.33%	-28.38%
4	Isha Gandhi	2,475	4.95%	-	0.00%	4.95%
5	Bhavika Gandhi	2,475	4.95%	-	0.00%	4.95%
6	Bhavya Gandhi	500	1.01%	-	0.00%	1.01%
		48,500	97.00%	30,000	100.00%	

3.5 Pursuant to the approval of the Board of Directors at their meeting dated 13 December 2023, the Company has issued 20,000 fully paid up equity shares to the existing eligible shareholders on a right basis in the ratio of 2 (two) equity shares for every 3 (Three) equity shares held by them on the record date of 13 December 2023.

4 Reserves and surplus	As at	As at
	31 December 2023	31 March 2023
Surplus of Statement of Profit and Loss		
As per the last Balance Sheet	460.87	158.93
Add: Net profit for the period/ year transferred from Statement of Profit and Loss	1,096.76	301.95
Total	1,557.63	460.87



Jax



5	Long-term provisions	As at	As at
		31 December 2023	31 March 2023
	Provision for employee benefit - Gratuity (Refer note 31.2)	29.38	26.85
	Total	29.38	26.85

6	Short term borrowing	As at	As at
		31 December 2023	31 March 2023
	Unsecured - From related parties (Refer note 6.1 and note 30)	-	3.50
	Total	-	3.50

- 6.1 Unsecured loans from related parties are in the nature of current account transactions, repayable on demand and in accordance with the terms of agreement and also interest free.

7	Trade payables	As at	As at
		31 December 2023	31 March 2023
	Amount due to micro, small and medium enterprises (Refer note 7.1)	107.74	303.51
	Amount due to other than micro, small and medium enterprises	11.01	18.72
	Amount due to related party (Refer Note 30)	0.45	196.17
	Total	119.20	518.40

- 7.1 Disclosure u/s 22 of Micro, Small and Medium Enterprises Development Act, 2006

Disclosure of outstanding dues to vendors registered with appropriate authority under the Micro, Small and Medium Enterprises Development Act, 2006 is to the extent of information available with the Company. Disclosure required under the Act are as given below:

Particulars	As at	As at
	31 December 2023	31 March 2023
a) Principal amount and the interest due thereon remaining unpaid to any supplier at the end of each accounting period/year		
(i) Principal	107.74	303.51
(ii) Interest	4.38	-
b) the amount of interest paid by the buyer in terms of section 16 of the Micro, Small and Medium Enterprises Development Act, 2006, along with the amount of the payment made to the supplier beyond the appointed day during each accounting period/year	-	-
c) the amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the Micro, Small and Medium Enterprises Development Act, 2006;	-	-
d) the amount of interest accrued and remaining unpaid at the end of each accounting period/ year	4.38	-
e) the amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under section 23 of the Micro, Small and Medium Enterprises Development Act, 2006	-	-

The Company has disclosed the suppliers who have registered themselves under "Micro, Small and Medium Enterprises Development Act, 2006" to the extent they have identified on the basis of information available with the Company.



Ja



7.2 Trade payable ageing

Particulars	As at	As at
	31 December 2023	31 March 2023
Micro, small and medium enterprises		
Less than 1 year	107.56	303.51
1-2 years	0.18	-
2-3 years	-	-
More than 3 years	-	-
Total	107.74	303.51
Others		
Less than 1 year	11.46	25.17
1-2 years	-	107.71
2-3 years	-	82.01
More than 3 years	-	-
Total	11.46	214.89

8 Other current liabilities	As at	As at
	31 December 2023	31 March 2023
Other accrued liabilities	17.42	0.33
Employee related payables (Refer note 30)	27.25	188.76
Statutory dues	129.82	41.06
Other liabilities	0.02	0.27
Total	174.51	230.41

9 Short-term provisions	As at	As at
	31 December 2023	31 March 2023
Provision for employee benefit		
- Gratuity (Refer note 31.2)	2.32	0.06
Provision for income tax (net)	126.32	-
Total	128.64	0.06



Amwill Health Care Limited; Formerly known as Amwill Health; Care Private Limited)

CIN: U36994KA2017PLC105721

Notes to Special Purpose Interim Financial Statements for the period ended 31 December, 2023

(All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)


10 Property, plant and equipment

Description	Computers	Office equipments	Furniture and fixtures	Vehicles (Refer note 10.1)	Electrical Fittings	Plant and Machinery	Total Owned assets
Gross block							
Balance as at 1 April 2022	7.86	28.19	3.17	23.51	0.82	-	63.55
Additions	-	4.23	0.29	26.95	-	-	31.47
Disposals/transferred	-	-	-	-	-	-	-
Balance as at 31 March 2023	7.86	32.42	3.46	50.46	0.82	-	95.02
Balance as at 1 April 2023	7.86	32.42	3.46	50.46	0.82	-	95.02
Additions	0.68	1.31	-	2.66	-	24.78	29.43
Disposals/transferred	-	-	-	(5.69)	-	-	(5.69)
Re-classification (Refer note 10.2)	-	(24.82)	-	-	-	24.82	-
Balance as at 31 December 2023	8.53	8.91	3.46	47.43	0.82	49.60	118.75
Accumulated depreciation							
Balance as at 1 April 2022	3.59	15.00	0.82	7.24	0.21	-	24.87
Depreciation for the year	2.70	7.67	0.66	10.01	0.16	-	21.20
Deductions	-	-	-	-	-	-	-
Balance as at 31 March 2023	6.29	20.57	1.48	17.25	0.37	-	46.07
Balance as at 1 April 2023	6.29	20.57	1.48	17.25	0.37	-	46.07
Depreciation for the year	0.82	1.59	0.39	7.49	0.09	4.35	14.73
Deductions	-	(17.32)	-	(3.01)	-	-	(3.01)
Re-classification (Refer note 10.2)	-	-	-	-	-	17.32	-
Balance as at 31 December 2023	7.11	4.94	1.87	21.73	0.46	21.67	57.79
Net block							
As At 31 March 2023	1.57	11.75	1.98	33.21	0.45	-	48.95
As At 31 December 2023	1.42	3.97	1.59	25.69	0.36	27.92	60.95

10.1 Net block of vehicles includes Rs. 6.48 as at 31 December 2023 (31 March 2023: Rs. 8.46) which is in the name of the director of the Company. Process of transfer in the of the Company is in progress.

10.2 Laser machines have been re-classified from office equipments to plant and machinery during the period.

10.3 The amount of capital commitment is disclosed in note 35.1



Amwill Health Care Limited (Formerly known as Amwill Health Care Private Limited)

CIN: U36994KA2017PLC105721

Notes to Special Purpose Interim Financial Statements for the period ended 31 December 2023

(All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

11 Intangible assets

Description	Trademarks	Software	Total
Gross block			
Balance as at 1 April 2022	7.59	1.69	9.29
Additions during the year	-	-	-
Balance as at 31 March 2023	7.59	1.69	9.29
Balance as at 1 April 2023	7.59	1.69	9.29
Additions during the year	0.82	-	0.82
Balance as at 31 December 2023	8.41	1.69	10.11
Amortisation			
Balance as at 1 April 2022	3.43	0.22	3.65
Amortisation for the year	1.88	0.66	2.54
Balance as at 31 March 2023	5.31	0.88	6.19
Balance as at 1 April 2023	5.31	0.88	6.19
Amortisation for the year	1.06	0.27	1.33
Balance as at 31 December 2023	6.36	1.16	7.52
Net block			
As At 31 March 2023	2.29	0.81	3.10
As At 31 December 2023	2.05	0.53	2.59

11.1 Software is other than internally generated software.

11.2 The Company has not revalued its Intangible assets



Amwill Health Care Limited (Formerly known as Amwill Health Care Private Limited)
 CIN: U36994KA2017PLC105721
 Notes to Special Purpose Interim Financial Statements for the period ended 31 December 2023
 (All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

12 Capital work-in-progress

Description	Office Equipment
Balance as at 1 April 2022	-
Additions	-
Capitalised during the year	-
Balance as at 31 March 2023	-
Balance as at 1 April 2023	-
Additions	21.25
Capitalised during the year	-
Balance as at 31 December 2023	21.25

12.1 Ageing schedule for Capital-work-in-progress:

Ageing	As at 31 Dec 2023			As at 31 March 2023		
	Projects in progress	Projects temporarily suspended	Total	Projects in progress	Projects temporarily suspended	Total
Less than 1 year	21.25	-	21.25	-	-	-
1-2 years	-	-	-	-	-	-
2-3 years	-	-	-	-	-	-
More than 3 years	-	-	-	-	-	-
Total	21.25	-	21.25	-	-	-

Note: There are no projects under Capital Work in progress where the completion is overdue or has exceeded its cost compared to its original plan.



[Handwritten signature]

Amwill Health Care Limited (Formerly known as Amwill Health Care Private Limited)
 CIN: U36994KA2017PLC105721
 Notes to Special Purpose Interim Financial Statements for the period ended 31 December 2023
 (All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

13 Intangible Assets under development :

Description	Trademarks
Balance as at 1 April 2022	-
Additions	-
Capitalised during the year	-
Balance as at 31 March 2023	-
Balance as at 1 April 2023	-
Additions	17.65
Capitalised during the year	-
Balance as at 31 December 2023	17.65

13.1 Ageing schedule of Intangible assets under development:

Ageing	As at 31 December 2023	As at 31 March 2023
Less than 1 Year	17.65	-
1-2 Years	-	-
2-3 Years	-	-
More than 3 Years	-	-
Total	17.65	-



[Handwritten signature]

14	Deferred tax assets (net)	As at 31 December 2023	As at 31 March 2023
	Deferred tax assets		
	Difference in net carrying value of property, plant and equipment and intangible assets as per income tax and books	7.71	7.30
	Expense allowed on payment basis as per Income tax act, 1961	1.20	6.77
	Total	8.91	14.07

15	Long term loans and advances (Unsecured, considered good except otherwise stated)	As at 31 December 2023	As at 31 March 2023
	Security deposits	4.99	4.99
	Total	4.99	4.99

16	Other non-current assets (Unsecured, considered good except otherwise stated)	As at 31 December 2023	As at 31 March 2023
	Income tax assets (net)	-	33.58
	Total	-	33.58

17	Inventories	As at 31 December 2023	As at 31 March 2023
	Materials in hand	104.63	317.96
	Total	104.63	317.96

17.1 Inventories are valued at cost or net realizable value whichever is lower. Refer note 2.10 for detailed accounting policy for inventory valuation.

18	Trade receivable (Unsecured, considered good unless otherwise stated)	As at 31 December 2023	As at 31 March 2023
	(From the date they are due for payment)		
	Outstanding for a period exceeding six months	3.82	4.26
	Other debts	799.41	118.94
	Total	803.23	123.20

18.1 Trade receivable comprise of receivable from Amderma Healthcare LLP amounting to Rs. 786.22 (As at 31 March 2023: Rs. 103.61) in which directors of the Company are partners (Also refer note 30).

18.2 There are no unbilled receivables, hence the same is not disclosed in the ageing schedule.

18.3 Trade receivable ageing

Particulars	As at 31 December 2023	As at 31 March 2023
Undisputed Trade Receivables-considered good		
- Less than 6 months	799.41	118.94
- 6 Months - 1 year	3.41	3.64
- 1-2 years	0.41	0.62
- 2-3 years	-	-
- More than 3 years	-	-
Sub-total	803.23	123.20
Disputed Trade Receivables-considered good		
- Less than 6 months	-	-
- 6 Months - 1 year	-	-
- 1-2 years	-	-
- 2-3 years	-	-
- More than 3 years	-	-
Sub-total	-	-
Total of trade receivable	803.23	123.20



Type your name here



Jan

19	Cash and bank balances	As at	As at
		31 December 2023	31 March 2023
A. Cash and cash equivalents			
	Cash on hand	8.92	8.65
	Balance with bank in current accounts	444.93	2.09
	Fixed deposits with bank- Sweep-in facility	291.85	573.30
	Sub total (A)	745.70	584.04
B. Other bank balance			
	Fixed deposits with bank (maturity period more than three months but less than twelve months)	102.85	101.32
	Sub total (B)	102.85	101.32
	Total (A+B)	848.55	685.36

20	Short-term loans and advances (Unsecured, considered good except otherwise stated)	As at	As at
		31 December 2023	31 March 2023
	Advance to vendors	47.42	3.99
	Advance to employees (Refer note 20.1 and note 30)	79.10	1.53
	Total	126.52	5.53

- 20.1 Advances to employees also includes Rs. 45.16 (31 March 2023: Nil) interest free advance given to directors against salary in accordance with employee advance policy of the Company. These are adjusted against monthly salary in accordance with policy of the Company.

21	Other current assets (Unsecured, considered good except otherwise stated)	As at	As at
		31 December 2023	31 March 2023
	Prepaid expenses (Refer note 21.1)	12.54	0.18
	Interest accrued on fixed deposits	2.55	6.17
	Total	15.09	6.35

- 21.1 The above includes expenses in relation to proposed Initial Public Offering aggregating to Rs. 11.00 (31 March 2023: Nil) which would be which would be first adjusted against the security premium (if available) or charged to statement of profit and loss in accordance with accounting policy of the Company. In case of offer for sale by existing shareholders, proportionate IPO expenses will be recovered from selling shareholders.



22	Revenue from operations	For the period ended 31 December 2023	Year ended 31 March 2023
	Sale of products (net of Goods and Service tax) (Refer note 30 and note 33)	3,578.83	3,016.63
	Total	3,578.83	3,016.63
23	Other Income	For the period ended 31 December 2023	Year ended 31 March 2023
	Interest income on		
	- Deposits with bank	23.24	9.98
	- Income tax refund	0.34	1.64
	Profit on sale of property, plant and equipment	2.78	-
	Total	26.36	11.62
24	Materials produced	For the period ended 31 December 2023	Year ended 31 March 2023
	Materials produced during the period/year	754.30	1,019.04
	Total	754.30	1,019.04
25	Changes in inventories of Materials in hand	For the period ended 31 December 2023	Year ended 31 March 2023
	Inventories at the beginning of the period / year	317.96	205.76
	Inventories at the end of the period / year	104.63	317.96
	Decrease / (Increase) in inventories of materials in hand	213.33	(112.20)
26	Employee benefits expenses	For the period ended 31 December 2023	Year ended 31 March 2023
	Salaries and wages (Refer note 30)	381.17	690.14
	Contribution to provident and other funds		
	- Provident fund (Refer note 31.1)	26.73	40.40
	- Other fund (Refer note 31.1)	0.01	0.01
	Gratuity expenses (Refer note 31.2)	4.78	26.92
	Staff welfare charges	7.60	4.87
	Total	420.29	762.34
27	Finance cost	For the period ended 31 December 2023	Year ended 31 March 2023
	Other borrowing cost	4.38	-
	Total	4.38	-



28 Depreciation and amortisation expense	For the period ended	Year ended
	31 December 2023	31 March 2023
Depreciation of property, plant and equipment (Refer note 10)	14.73	21.20
Amortization of intangible assets (Refer note 11)	1.33	2.54
Total	16.06	23.74

29 Other expenses	For the period ended	Year ended
	31 December 2023	31 March 2023
Advertisement and sales promotion	301.00	293.25
Discount allowed (Net) (Refer note 30)	175.29	172.01
Commission expenses (Refer note 30)	155.63	244.08
Conveyance and Marketing expenses	30.34	33.47
Legal and professional fees (Refer note 30)	20.83	130.10
Freight Outward	2.42	1.68
Power and fuel	3.87	4.15
Rent expenses	5.36	7.14
Printing and stationery	9.56	8.49
Expired goods written off	3.09	4.90
Rates and taxes	0.09	0.02
Insurance	0.79	0.04
Repair and maintenance		
- Computer & Software maintenance	1.12	1.31
- Others	1.33	3.27
Postage, telegrams and telephone charges	0.16	0.22
License & registration fees	0.33	0.38
Bad debts written off	0.05	4.58
General office and other expenses	1.66	18.12
Audit remuneration (Refer note 29.1)	6.75	5.20
Total	719.67	932.41

29.1 Audit remuneration*	For the period ended	Year ended
	31 December 2023	31 March 2023
Audit fees		
Statutory audit fees	6.75	4.20
Tax audit fees	-	1.00
Total	6.75	5.20

*Excluding goods and service tax



30 Related party disclosures

(i) Name and relationships of related parties:

(i) Key Management Personnel ('KMP')

Mr. Tarun Gandhi – Director
Mr. Anand Gandhi – Director
Dr. Rekha Jagadish - Non Executive Director (w.e.f. 28 December 2023)

(ii) Independent Directors

Mr. Sambhav Mehta - Additional Director (w.e.f. 04 January 2024)

(iii) Relatives of Key Management Personnel ('KMP')

(only where there are transactions)

Mrs. Shashikala - Mother of Director
Mrs. Isha Gandhi - Spouse of Director
Mrs. Bhavika Gandhi - Spouse of Director
Mrs. Bhavya Gandhi - Sister of Director

(iv) Enterprise over which the Key Management Personnel have significant influence

(only where there are transactions/balances)

Amderma Healthcare LLP
Ample Pharma

(ii) Transactions with related parties:

Nature of transactions	Name of Party	For the period ended 31 December 2023	Year ended 31 March 2023
Sale of Goods	Amderma Healthcare LLP	3,543.62	2,963.58
	Ample Pharma	-	0.11
Discount Allowed (net)	Amderma Healthcare LLP	175.34	171.94
Commission expense	Amderma Healthcare LLP	7.10	7.87
Reimbursement of expenses	Amderma Healthcare LLP	1.67	0.28
	Ample Pharma	0.11	0.51
Remuneration paid	Anand Gandhi	71.08	185.70
	Tarun Gandhi	71.08	185.70
Salary paid	Shashikala	31.49	56.25
	Isha Gandhi	31.49	65.25
	Bhavika Gandhi	31.49	65.25
	Anand Gandhi	22.58	-
Advance against salary given	Tarun Gandhi	22.58	-
	Shashikala	9.38	-
	Isha Gandhi	9.38	-
	Bhavika Gandhi	9.38	-
	Anand Gandhi	0.00	5.81
Repayment of unsecured loans	Tarun Gandhi	-	5.31
	Shashikala	3.50	-
	Anand Gandhi	-	1.67
Proceeds from unsecured loans	Tarun Gandhi	-	0.85
	Shashikala	-	-
	Anand Gandhi	8.00	48.00
Professional fees	Tarun Gandhi	8.00	48.00
	Bhavya Gandhi	4.50	6.61



(iii) Related party outstanding balances

Nature of Balance	Name of Party	As at 31 December 2023	As at 31 March 2023
Remuneration payable	Anand Gandhi	-	-
	Tarun Gandhi	-	16.70
	Shashikala	-	127.86
	Isha Gandhi	-	9.52
	Bhavika Gandhi	-	9.52
Advance salary	Anand Gandhi	22.58	-
	Tarun Gandhi	22.58	-
	Shashikala	9.38	-
	Isha Gandhi	9.38	-
	Bhavika Gandhi	9.38	-
Trade receivable	Amderma Healthcare LLP	786.22	103.61
Other payables	Anand Gandhi	-	4.04
Reimbursement payable	Ample Pharma	-	0.51
Unsecured loans received	Anand Gandhi	-	0.00
	Tarun Gandhi	-	-
	Shashikala	-	3.50
Professional fees payable	Anand Gandhi	-	88.71
	Tarun Gandhi	-	67.43
	Shashikala	-	29.55
	Bhavika Gandhi	0.45	5.94

(iv) As at 31 December 2023, the Company has not granted any loans to the promoters, directors, KMPs and the related parties (as defined under Companies Act, 2013), either severally or jointly with any other person (31 March 2023: Nil). Loans given to employees as per the Company's policy are not considered for the purposes of disclosure under Section 186(4) of the Companies Act, 2013.

(v) Transaction with related parties are disclosed from the date when relationship came into existence and upto the date of relationship existed

31 Employee Benefit Obligations

31.1 Disclosures for defined contribution plan

The Company has certain defined contribution plans. The obligation of the Company is limited to the amount contributed and it has no further contractual obligation. Following are the details regarding Company's contributions made during the period/year

Particulars	For the period ended 31 December 2023	Year ended 31 March 2023
Provident fund and pension fund	26.73	40.40
Karnataka labour welfare fund (KLWF)	0.01	0.01
Total	26.74	40.41


31.2 Disclosures for defined benefit plans

(i) Gratuity

In accordance with the Payment of Gratuity Act, 1972, the Company provides for gratuity, a defined benefit retirement plan ("the Plan") covering eligible employees. The Plan provides for a lump sum payment to vested employees on retirement, death, incapacitation or termination of employment of amounts that are based on salary and tenure of employment. Liabilities with regard to the Gratuity Plan are determined by actuarial valuation using Projected Unit Credit method. The Gratuity plan is non-funded.

The actuarial assumptions used in estimation of actuarial liability for the Gratuity Plan were as follows:

Particulars	For the period ended 31 December 2023	Year ended 31 March 2023
Discount rate (per annum)	7.41%	7.39%
Salary Escalation (per annum)	8.00%	8.00%
Attrition Rate (per annum)	6.00%	5.00%
Mortality Rate	100% of Indian Assured lives Mortality (2012-14)	



The following table sets out the funded status of the Gratuity Plan and the amounts recognized in the financial statements:

Changes in the present value of obligations	As at 31 December 2023	As at 31 March 2023
Liability at the beginning of the year	26.92	-
Current service cost	6.13	13.91
Interest cost	1.49	-
Actuarial (gain)/loss on obligations	(2.85)	-
Past service cost	-	13.00
Benefits paid	-	-
Liability at the end of the period/year	31.69	26.92
Non-current portion of defined benefit obligation	29.38	26.85
Current portion of defined benefit obligation	2.32	0.06

Table of recognition of actuarial gain / loss	For the period ended 31 December 2023	Year ended 31 March 2023
Actuarial (gain)/ loss on obligation for the period	(2.85)	-
Actuarial gain/ (loss) on assets for the period	-	-
Actuarial (gain)/ loss recognized in Statement of Profit and Loss	(2.85)	-

Breakup of actuarial (gain) /loss	For the period ended 31 December 2023	Year ended 31 March 2023
Actuarial loss/(gain) arising from change in demographic assumption	0.97	-
Actuarial loss arising from change in financial assumption	(0.06)	-
Actuarial loss/(gain) arising from experience	(3.76)	-
Total	(2.85)	-

Amount recognized in the Balance Sheet	As at 31 December 2023	As at 31 March 2023
Liability at the end of the period/ year	31.69	26.92
Fair value of plan assets at the end of the period/ year	-	-
Total	31.69	26.92

Expenses recognized in the statement of profit and loss	For the period ended 31 December 2023	Year ended 31 March 2023
Service cost	6.13	13.91
Interest cost	1.49	-
Past service cost	-	13.00
Actuarial loss/(gain)	(2.85)	-
Expenses recognised in the Statement of Profit or Loss	4.77	26.92

Sensitivity analysis of benefit obligation (Gratuity)	As at 31 December 2023	As at 31 March 2023
a) Impact of change in discount rate		
Present value of obligation at the end of the period		
a) Impact due to increase of 0.50%	(1.39)	(1.61)
b) Impact due to decrease of 0.50%	1.50	1.76
b) Impact of change in salary growth		
Present value of obligation at the end of the period		
a) Impact due to increase of 0.50%	0.74	0.92
b) Impact due to decrease of 0.50%	(0.68)	(0.90)



Jaal



Pay-out analysis	As at 31 December 2023	As at 31 March 2023
Expected Outgo First	2.32	0.06
Expected Outgo Second	1.19	0.05
Expected Outgo Third	1.59	0.06
Expected Outgo Fourth	2.08	1.22
Expected Outgo Fifth	1.48	2.48
Expected Outgo Sixth	1.39	1.06
Expected Outgo 6 years and above	21.64	21.99

32 Earning Per Share

Particulars	For the period ended 31 December 2023	Year ended 31 March 2023
Net profit after tax	1,096.76	301.95
Weighted average number of equity shares in calculating basic and diluted EPS (Refer note 32.1)	49,940	46,668
Face value of share in rupees	10	10
Earnings per share (basic and diluted)- Restated	2,196.14	647.01
Reported EPS in respected audited financial statements	2,196.14	1,005.49

32.1 Weighted average number of equity shares outstanding in all the periods also includes impact of bonus component on rights issue.

33 Segment reporting

The Company operates in only one segment i.e. dealing in pharma products. Accordingly there is no reportable segment in accordance with Accounting Standard 17 - Segment Reporting. Further, entire operations are located in India, hence there is no reportable geographical segment.

34 Foreign currency exposure and derivative contracts

Foreign currency exposure outstanding as on 31 December 2023: Nil (31 March 2023: Nil). There are no outstanding derivative contracts as on 31 December 2023 (31 March 2023: Nil).

35 Capital commitments, other commitments and contingent liabilities

35.1 Capital commitments

Particulars	As at 31 December 2023	As at 31 March 2023
Capital commitments (Net of capital advances)	3.75	-

35.2 Contingent liabilities (to the extent not provided for)

There are no contingent liabilities as at 31 December 2023 (31 March 2023 - Nil).



Amwill Health Care Limited (Formerly known as Amwill Health Care Private Limited)

CIN: U36994KA2017PLC105721

Notes to Special Purpose Interim Financial Statements for the period ended 31 December 2023

(All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

36 Financial Ratios

(a) Ratios analysis & it's elements

Financial ratios	Numerator	Denominator	For the period ended	Year ended 31 March 2023
Current Ratio (times)	Current assets	Current liabilities	4.49	1.51
Debt-Equity Ratio (times)	Debt :- long term borrowings + short term borrowings	Equity: Total shareholder's funds	N.A.	0.01
Debt Service Coverage Ratio	Earning available for debt services :- net profit before tax + non cash expenses tax Depreciation and Amortisation) + interest expense on borrowings	Interest + Current Maturities of long term borrowings:- interest expenses on borrowings and current maturities of long term borrowings	N.A.	N.A.
Return on Equity Ratio (%)	Total Profit / (loss) for the year	Total shareholder's funds	70.19%	65.09%
Inventory turnover ratio (times)	Cost of good sold :- Materials produced+ changes in inventories of materials in hand	Average Inventory	4.58	3.46
Trade Receivables turnover ratio (times)	Revenue from operations	Average Trade Receivables	1.93	7.16
Trade payables turnover ratio (times)	Materials produced	Average trade payables	0.59	0.67
Net capital turnover ratio (times)	Revenue from operations	Working capital	2.43	7.81
Net profit ratio (%)	Profit / (loss) after tax	Revenue from operations	30.65%	10.01%
Return on Capital employed (%)	Earning before interest & taxes (EBIT) :- profit / (loss) before tax + interest expenses	Capital Employed :- total shareholder's funds + borrowings	91.40%	79.17%
Return on investment (%)	Profit / (loss) after tax	Equity shareholders' fund	70.19%	65.09%



Jan



Amwill Health Care Limited (Formerly known as Amwill Health Care Private Limited)

CIN: U36994KA2017PLC105721

Notes to Special Purpose Interim Financial Statements for the period ended 31 December 2023

(All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

(b) Change in Ratios

Financial ratios	% change from 31 March 2023 to 31 December 2023*	% change from 31 March 2022 to 31 March 2023
Current Ratio (times)	NA	34%
Debt-Equity Ratio (times)	NA	-90%
Debt Service Coverage Ratio	NA	NA
Return on Equity Ratio (%)	NA	-60%
Inventory Turnover Ratio	NA	-10%
Trade Receivables turnover ratio (times)	NA	174%
Trade payables turnover ratio (times)	NA	20%
Net capital turnover ratio (times)	NA	-82%
Net profit ratio (%)	NA	5%
Return on Capital employed (%)	NA	-59%
Return on investment (%)	NA	-60%

* % changes in Ratio is not applicable for the period as the same is for interim period and hence not comparable

(c) Reason/ remark for change in ratio more than 25%

Financial ratios	% change from 31 March 2023 to 31 December 2023*	% change from 31 March 2022 to 31 March 2023
Current Ratio (times)	NA	Due to increase in current assets
Debt-Equity Ratio (times)	NA	Due to repayment of borrowings
Return on Equity Ratio (%)	NA	Due to increase in profit, there is increase in shareholder's funds
Inventory Turnover Ratio	NA	NA
Trade Receivables turnover ratio (times)	NA	Due to increase in revenue
Trade payables turnover ratio (times)	NA	NA
Net capital turnover ratio (times)	NA	Due to increase in Working capital
Net profit ratio (%)	NA	NA
Return on Capital employed (%)	NA	Due to increase in Capital employed
Return on investment (%)	NA	Due to increase in profit, there is increase in shareholder's funds

* Reason for changes in Ratio is not applicable for the period as the same is for interim period and hence not comparable

37 Additional Regulatory Information

(a) Details of Benami Property held

The Company do not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.

(b) Details of Loans and advances

There are no loans and advances granted to promoters, directors, key managerial personnel (KMPs) and the related parties which are repayable on demand or without specifying any terms or period of repayment except salary advance given to the directors and related parties in accordance with the employee advance policy of the company.

(c) Wilful Defaulter

The Company has not been declared as a wilful Defaulter by any Financial Institution or bank as at the date of Balance Sheet.

(d) Relationship with Struck off Companies

The Company do not have any transactions with struck off companies.

(e) Registration of charges or satisfaction with Registrar of Companies (ROC)

The Company has no pending charges or satisfaction which are yet to be registered with the ROC beyond the Statutory period.

(f) Compliance with number of layers of companies

The Company has complied with the provision of the number of layers prescribed under clause (87) of section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017.

(g) Compliance with approved Scheme(s) of Arrangements

There are no Schemes of Arrangements has been approved by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013.



Amwill Health Care Limited (Formerly known as Amwill Health Care Private Limited)

CIN: U36994KA2017PLC105721


Notes to Special Purpose Interim Financial Statements for the period ended 31 December 2023

(All Amount in Indian Rupees and in lakhs, other than shares and per share amounts, unless otherwise stated)

- (h) **Discrepancy in utilization of borrowings**
There are no borrowings during the period except general demand loans taken from the directors in earlier years, hence the question for reporting under this clause does not arise
- (i) **Utilisation of Borrowed funds and share premium:**
There are no borrowings during the period except general demand loans taken from the directors in earlier years, hence the question for reporting under this clause does not arise
- (j) **Undisclosed Income**
The Company has no transaction that is not recorded in the books of accounts that has been surrendered or disclosed as Income during the period in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961)
- (k) **Details of Crypto Currency or Virtual Currency**
The Company has not traded or invested in Crypto currency or Virtual Currency.
- 38 **Additional information required under Schedule III of the Companies Act, 2013 to the extent applicable has been given below.**
There are no earnings and expenditure incurred in Foreign currency in the current period (For year ended 31 March 2023 : Nil). Also, there are no remittances in foreign currency on account of dividends during the current period (For year ended 31 March 2023 : Nil)
- 39 **Code on Social Security, 2020**
The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the Company towards Provident Fund and Gratuity. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its evaluation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published
- 40 **Change in name of the company subsequent to period end**
Pursuant to resolution passed by the Members in the Extraordinary General Meeting dated 29 December 2023 and as approved by the Registrar of the Companies subsequent to period end w.e.f. 25 January 2024, the Company has been converted from Private Limited Company into a Public Limited Company including adoption of new Memorandum of Association and new Articles of Association as applicable to the Public Company in place of existing Memorandum of Association and Articles of Association of the Company
- 41 The Company elected to exercise the option permitted under section 115BAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019 from financial year 2021-22 onwards. Accordingly, Income Tax rate prescribed in the said section i.e. 22% as increased by applicable surcharge (10%) and cess (4%) is applicable to the Company from that financial year.
- 42 The Previous year's figures have been regrouped /reclassified, wherever considered necessary.

As per our report of even date

For SKLR & Co. LLP
Chartered Accountants
Firm Registration No.: W100362


Lakshmi Bada
Partner

Membership No. 155999
UDIN No. 24155999BKAIZO9276

Place: Mumbai
Date: 25-01-2024



For and on behalf of the Board of Directors of
Amwill Health Care Limited (Formerly known as Amwill
Health Care Private Limited)


Tarun Gandhi
Director
DIN: 07854699

Place: Bangalore
Date: 25-01-2024


Anand Gandhi
Director
DIN: 07854706

Place: Bangalore
Date: 25-01-2024

